#NeerajAggarwal presents final overall survival from #TALAPRO2 trial - patients w metastatic #prostatecancer lived longer and had improved time to chemo. Only 2 MDS/AML events in entire trial. Supporting the talazoparib-enzalutamide approval. #GU25 @ascocancer.bsky.social

These are the 2 key slides from the #Talapro2 presentation @asco #GU25

Where HR crosses 1.0 in pts w/no known
HRR mutation status & Gd3 toxicity difference of 75% vs 45%

I think there is still much to discussion to be had of value of #PARP +#ARPI in unselected #ProstateCancer

Worth revisiting the #BRCAway trial from #GU24 in the context of #GU25 and #Talapro2

With regard to evaluation of sequencing #Parp and #ARPI the numbers of pts are very small (8 with cross over) and the CIs are very wide.
#ProstateCancer

A related question on #Talapro2 that remains unanswered is sequencing of #ARPI & #parp aside from a very small phase 2 trial with far too few pts

Sequencing #Parp would defer toxicity for mos-yrs

& worth noting that low% of mCRPC pts getting 2nd line tx predates #parp era
#GU25

Sadly only 17% of pts in #Talapro2 study were treated with subsequent #Parp

That is one among many questions about these parp and #arpi studies raised in this commentary @asco #GU25 #ProstateCancer

ascopubs.org/doi/10.1200/...

The OncoAlert🚨Newsletter, EVERY WEEK! This week Covering April 11-17, 2025
REGISTER at oncoalert360.com OR oncoalert.m-pages.com/nhMpwe/oncoa...

✅TALAPRO2 in #ProstateCancer
✅SBRT☢️ & IO in #KidneyCancer
✅ Challenges in #SCLC heterogeneity &Plasticity🫁
✅OptiTROP-Breast01 in #BreastCancer

🔥 Exciting #ProstateCancer Abstracts from #ASCOGU:
📌 LBA18 – Final overall survival results of the phase 3 #TALAPRO2 trial.
📌 Abstract 21 – Transdermal #Estradiol (#tE2) patches + #ARPIs in metastatic (#M1) prostate cancer.
📌 Abstract 22 – #Metastases-directed therapy in oligometastatic #CRPC.

#TALAPRO2: First patient-level rPFS–OS correlation analysis for a PARP inhibitor in first-line #mCRPC — and results held across unselected, HRR-deficient, and BRCAm subgroups.

#AUA26 @huntsmancancer.bsky.social #pcsm

Learn more: www.onclive.com/view/talapro...

I think this trial raises two questions. a) Should the Talapro2 regimen or triplet with docetaxel be used in these patients? b)Why was MLH1 included in this analysis as I would not usually consider this in the HRR system?